Skip to main content
Top
Published in: Sleep and Breathing 2/2014

01-05-2014 | Original Article

Influence of CPAP treatment on airway and systemic inflammation in OSAS patients

Authors: Harun Karamanlı, Duygu Özol, K. Serife Ugur, Zeki Yıldırım, Ferah Armutçu, Bulent Bozkurt, Ramazan Yigitoglu

Published in: Sleep and Breathing | Issue 2/2014

Login to get access

Abstract

Aim

Obstructive sleep apnea syndrome (OSAS) is characterized by recurrent respiratory disorders in the upper airways during sleep. Although continuous positive airway pressure (CPAP) has been accepted to be the most effective treatment for OSAS, its role on inflammation remains debatable. In this study, our aim was to examine the influence of 3 months of CPAP treatment on tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), 8-isoprostane, and peroxynitrite levels in exhaled breathing condensates (EBC) and serum.

Methods

Thirty-five patients who were newly diagnosed as moderate or severe OSAS with full night polysomnography and used CPAP therapy regularly for 3 months were included in the study. Polysomnography, spirometric tests, fasting blood samples, and EBC were ascertained on entry into the study and after 3 months of treatment. All patients were assessed monthly for treatment adherence and side effects.

Results

We found that all polysomnographic parameters were normalized after CPAP therapy in the control polysomnogram. Also, all markers in EBC and nitrotyrosine and 8-isoprostane levels in serum were decreased significantly with CPAP treatment. Sedimentation rate, C-reactive protein, IL-6, and TNF-α remained unchanged in serum after treatment. We found that baseline nitrotyrosine levels were significantly correlated with apnea–hypopnea index, oxygen desaturation index, and percent time in SpO2 < 90 % (p < 0.01).

Conclusions

CPAP therapy has primarily a relevant impact on airways, and nitrotyrosine levels correlated well with severity of OSAS. This treatment decreases both inflammation and oxidative stress levels in airways in OSAS patients. Also, this treatment helps to decrease systemic oxidative stress levels in serum.
Literature
1.
go back to reference Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S (1993) The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 328:1230–1235PubMedCrossRef Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S (1993) The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 328:1230–1235PubMedCrossRef
2.
go back to reference Kohler M, Stradling JR (2010) Mechanisms of vascular damage in obstructive sleep apnea. Nat Rev Cardiol 7:677–685PubMed Kohler M, Stradling JR (2010) Mechanisms of vascular damage in obstructive sleep apnea. Nat Rev Cardiol 7:677–685PubMed
3.
go back to reference Ryan S, Taylor CT, McNicholas WT (2009) Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome? Postgrad Med J 85:693–698PubMedCrossRef Ryan S, Taylor CT, McNicholas WT (2009) Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome? Postgrad Med J 85:693–698PubMedCrossRef
4.
go back to reference Quercioli A, Mach F, Montecucco F (2010) Inflammation accelerates atherosclerotic processes in obstructive sleep apnea syndrome (OSAS). Sleep Breath 14:261–269PubMedCrossRef Quercioli A, Mach F, Montecucco F (2010) Inflammation accelerates atherosclerotic processes in obstructive sleep apnea syndrome (OSAS). Sleep Breath 14:261–269PubMedCrossRef
5.
go back to reference Takama N, Kurabayasi M (2009) Influence of untreated sleep-disordered breathing on the long-term prognosis of patients with cardiovascular disease. Am J Cardiol 103:730–734PubMedCrossRef Takama N, Kurabayasi M (2009) Influence of untreated sleep-disordered breathing on the long-term prognosis of patients with cardiovascular disease. Am J Cardiol 103:730–734PubMedCrossRef
6.
go back to reference Foresi A, Leone C, Olivieri D, Cremona G (2007) Alveolar-derived exhaled nitric oxide is reduced in obstructive sleep apnea syndrome. Chest 132:860–867PubMedCrossRef Foresi A, Leone C, Olivieri D, Cremona G (2007) Alveolar-derived exhaled nitric oxide is reduced in obstructive sleep apnea syndrome. Chest 132:860–867PubMedCrossRef
7.
go back to reference Alberti A, Sarchielli P, Gallinella E, Floridi A, Floridi A, Mazzotta G, Gallai V (2003) Plasma cytokine levels in patients with obstructive sleep apnea syndrome: a preliminary study. J Sleep Res 12:305–311PubMedCrossRef Alberti A, Sarchielli P, Gallinella E, Floridi A, Floridi A, Mazzotta G, Gallai V (2003) Plasma cytokine levels in patients with obstructive sleep apnea syndrome: a preliminary study. J Sleep Res 12:305–311PubMedCrossRef
8.
go back to reference Ciftci TU, Kokturk O, Bukan N, Bilgihan A (2004) Relationship between serum cytokine levels with obesity and obstructive sleep apnea syndrome. Cytokine 21:87–91CrossRef Ciftci TU, Kokturk O, Bukan N, Bilgihan A (2004) Relationship between serum cytokine levels with obesity and obstructive sleep apnea syndrome. Cytokine 21:87–91CrossRef
9.
go back to reference Kushida CA, Littner MR, Hirshkowitz M, Morgenthaler TI, Alessi CA, Bailey D, Boehlecke B, Brown TM, Coleman J Jr, Friedman L, Kapen S, Kapur VK, Kramer M, Lee-Chiong T, Owens J, Pancer JP, Swick TJ, Wise MS (2006) American Academy of Sleep Medicine Practice parameters for the use of continuous and bilevel positive airway pressure devices to treat adult patients with sleep-related breathing disorders. Sleep 29:375–380PubMed Kushida CA, Littner MR, Hirshkowitz M, Morgenthaler TI, Alessi CA, Bailey D, Boehlecke B, Brown TM, Coleman J Jr, Friedman L, Kapen S, Kapur VK, Kramer M, Lee-Chiong T, Owens J, Pancer JP, Swick TJ, Wise MS (2006) American Academy of Sleep Medicine Practice parameters for the use of continuous and bilevel positive airway pressure devices to treat adult patients with sleep-related breathing disorders. Sleep 29:375–380PubMed
10.
go back to reference Kushida CA, Morgenthaler TI, Littner MR, Alessi CA, Bailey D, Coleman J Jr, Friedman L, Hirshkowitz M, Kapen S, Kramer M, Lee-Chiong T, Owens J, Pancer JP (2006) American Academy of Sleep Practice parameters for the treatment of snoring and obstructive sleep apnea with oral appliances. Sleep 29:240–243PubMed Kushida CA, Morgenthaler TI, Littner MR, Alessi CA, Bailey D, Coleman J Jr, Friedman L, Hirshkowitz M, Kapen S, Kramer M, Lee-Chiong T, Owens J, Pancer JP (2006) American Academy of Sleep Practice parameters for the treatment of snoring and obstructive sleep apnea with oral appliances. Sleep 29:240–243PubMed
11.
go back to reference Skoczyński S, Ograbek-Król M, Tazbirek M, Semik-Orzech A, Pierzchała W (2008) Short-term CPAP treatment induces a mild increase in inflammatory cells in patients with sleep apnoea syndrome. Rhinology 46:144–150PubMed Skoczyński S, Ograbek-Król M, Tazbirek M, Semik-Orzech A, Pierzchała W (2008) Short-term CPAP treatment induces a mild increase in inflammatory cells in patients with sleep apnoea syndrome. Rhinology 46:144–150PubMed
12.
go back to reference Kohler M, Ayers L, Pepperell JC, Packwood KL, Ferry B, Crosthwaite N, Craig S, Siccoli MM, Davies RJ, Stradling JR (2009) Effects of continuous positive airway pressure on systemic inflammation in patients with moderate to severe obstructive sleep apnoea: a randomised controlled trial. Thorax 64:67–73PubMedCrossRef Kohler M, Ayers L, Pepperell JC, Packwood KL, Ferry B, Crosthwaite N, Craig S, Siccoli MM, Davies RJ, Stradling JR (2009) Effects of continuous positive airway pressure on systemic inflammation in patients with moderate to severe obstructive sleep apnoea: a randomised controlled trial. Thorax 64:67–73PubMedCrossRef
13.
go back to reference Fortuna AM, Miralda R, Calaf N, González M, Casan P, Mayos M (2011) Airway and alveolar nitric oxide measurements in obstructive sleep apnea syndrome. Respir Med 105:630–636PubMedCrossRef Fortuna AM, Miralda R, Calaf N, González M, Casan P, Mayos M (2011) Airway and alveolar nitric oxide measurements in obstructive sleep apnea syndrome. Respir Med 105:630–636PubMedCrossRef
14.
go back to reference Tamaki S, Yamauchi M, Fukuoka A, Makinodan K, Koyama N, Tomoda K, Yoshikawa M, Kimura H (2007) Production of inflammatory mediators by monocytes in patients with obstructive sleep apnea syndrome. Intern Med 48:1255–1262CrossRef Tamaki S, Yamauchi M, Fukuoka A, Makinodan K, Koyama N, Tomoda K, Yoshikawa M, Kimura H (2007) Production of inflammatory mediators by monocytes in patients with obstructive sleep apnea syndrome. Intern Med 48:1255–1262CrossRef
15.
go back to reference Iber C, Ancoli-Israel S, Chesson A, Quan SF (2007) The AASM manual for the scoring of sleep and associated events: rules, terminology, and technical specification. 1st ed. American Academy of Sleep Medicine, Westchester Iber C, Ancoli-Israel S, Chesson A, Quan SF (2007) The AASM manual for the scoring of sleep and associated events: rules, terminology, and technical specification. 1st ed. American Academy of Sleep Medicine, Westchester
16.
17.
go back to reference Salerno FG, Carpagnano E, Guido P, Bonsignore MR, Roberti A, Aliani M, Vignola AM, Spanevello A (2004) Airway inflammation in patients affected by obstructive sleep apnea syndrome. Respir Med 98:25PubMedCrossRef Salerno FG, Carpagnano E, Guido P, Bonsignore MR, Roberti A, Aliani M, Vignola AM, Spanevello A (2004) Airway inflammation in patients affected by obstructive sleep apnea syndrome. Respir Med 98:25PubMedCrossRef
18.
go back to reference Guasti L, Marino F, Cosentino M, Maroni L, Maresca AM, Colombo F, Maio RC, Castiglioni L, Saporiti F, Loraschi A, Gaudio G, Bernasconi A, Laurita E, Grandi AM, Venco A (2011) Cytokine production from peripheral blood mononuclear cells and polymorphonuclear leukocytes in patients studied for suspected obstructive sleep apnea. Sleep Breath 15:3–11PubMedCrossRef Guasti L, Marino F, Cosentino M, Maroni L, Maresca AM, Colombo F, Maio RC, Castiglioni L, Saporiti F, Loraschi A, Gaudio G, Bernasconi A, Laurita E, Grandi AM, Venco A (2011) Cytokine production from peripheral blood mononuclear cells and polymorphonuclear leukocytes in patients studied for suspected obstructive sleep apnea. Sleep Breath 15:3–11PubMedCrossRef
19.
go back to reference Devouassoux G, Lévy P, Rossini E, Pin I, Fior-Gozlan M, Henry M, Seigneurin D, Pépin JL (2007) Sleep apnoea is associated with bronchial inflammation and continuous positive airway pressure-induced airway hyperresponsiveness. J Allergy Clin Immunol 119:597–603PubMedCrossRef Devouassoux G, Lévy P, Rossini E, Pin I, Fior-Gozlan M, Henry M, Seigneurin D, Pépin JL (2007) Sleep apnoea is associated with bronchial inflammation and continuous positive airway pressure-induced airway hyperresponsiveness. J Allergy Clin Immunol 119:597–603PubMedCrossRef
20.
go back to reference Vgontzas AN, Zoumakis E, Bixler EO, Lin HM, Collins B, Basta M, Pejovic S, Chrousos GP (2008) Selective effects of CPAP on sleep apnoea-associated manifestations. Eur J Clin Invest 38:585–595PubMedCrossRef Vgontzas AN, Zoumakis E, Bixler EO, Lin HM, Collins B, Basta M, Pejovic S, Chrousos GP (2008) Selective effects of CPAP on sleep apnoea-associated manifestations. Eur J Clin Invest 38:585–595PubMedCrossRef
21.
go back to reference Mota PC, Drummond M, Winck JC, Santos AC, Almeida J, Marques JA (2011) APAP impact on metabolic syndrome in obstructive sleep apnea patients. Sleep Breath 15:665–672PubMedCrossRef Mota PC, Drummond M, Winck JC, Santos AC, Almeida J, Marques JA (2011) APAP impact on metabolic syndrome in obstructive sleep apnea patients. Sleep Breath 15:665–672PubMedCrossRef
22.
go back to reference Hegglin A, Schoch OD, Korte W, Hahn K, Hürny C, Münzer T (2012) Eight months of continuous positive airway pressure (CPAP) decrease tumor necrosis factor alpha (TNFA) in men with obstructive sleep apnea syndrome. Sleep Breath 16:405–412PubMedCrossRef Hegglin A, Schoch OD, Korte W, Hahn K, Hürny C, Münzer T (2012) Eight months of continuous positive airway pressure (CPAP) decrease tumor necrosis factor alpha (TNFA) in men with obstructive sleep apnea syndrome. Sleep Breath 16:405–412PubMedCrossRef
23.
go back to reference Yokoe T, Minoguchi K, Matsuo H, Oda N, Minoguchi H, Yoshino G, Hirano T, Adachi M (2003) Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 107:1129–1134PubMedCrossRef Yokoe T, Minoguchi K, Matsuo H, Oda N, Minoguchi H, Yoshino G, Hirano T, Adachi M (2003) Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 107:1129–1134PubMedCrossRef
24.
go back to reference Carpagnano GE, Spanevello A, Sabato R, Depalo A, Turchiarelli V, Foschino MP (2008) Exhaled pH, exhaled nitric oxide, and induced sputum cellularity in obese patients with obstructive sleep apnea syndrome. Transl Res 151:45–50PubMedCrossRef Carpagnano GE, Spanevello A, Sabato R, Depalo A, Turchiarelli V, Foschino MP (2008) Exhaled pH, exhaled nitric oxide, and induced sputum cellularity in obese patients with obstructive sleep apnea syndrome. Transl Res 151:45–50PubMedCrossRef
25.
go back to reference Weaver TE, Maislin G, Dinges DF, Bloxham T, George CF, Greenberg H, Kader G, Mahowald M, Younger J, Pack AI (2007) Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning. Sleep 30:711–719PubMedCentralPubMed Weaver TE, Maislin G, Dinges DF, Bloxham T, George CF, Greenberg H, Kader G, Mahowald M, Younger J, Pack AI (2007) Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning. Sleep 30:711–719PubMedCentralPubMed
27.
go back to reference Rosias PP, Robroeks CM, Kester A, den Hartog GJ, Wodzig WK, Rijkers GT, Zimmermann LJ, van Schayck CP, Jöbsis Q, Dompeling E (2008) Biomarker reproducibility in exhaled breath condensate collected with different condensers. Eur Respir J 31:934–942PubMedCrossRef Rosias PP, Robroeks CM, Kester A, den Hartog GJ, Wodzig WK, Rijkers GT, Zimmermann LJ, van Schayck CP, Jöbsis Q, Dompeling E (2008) Biomarker reproducibility in exhaled breath condensate collected with different condensers. Eur Respir J 31:934–942PubMedCrossRef
28.
go back to reference Yamauchi M, Kimura H (2008) Oxidative stress in obstructive sleep apnea: putative pathways to the cardiovascular complication. Antioxid Redox Signal 10:735–768 Yamauchi M, Kimura H (2008) Oxidative stress in obstructive sleep apnea: putative pathways to the cardiovascular complication. Antioxid Redox Signal 10:735–768
29.
go back to reference Petrosyan M, Perraki E, Simoes D, Koutsourelakis I, Vagiakis E, Roussos C, Gratziou C (2008) Exhaled breath markers in patients with obstructive sleep apnea. Sleep Breath 12:207–215PubMedCrossRef Petrosyan M, Perraki E, Simoes D, Koutsourelakis I, Vagiakis E, Roussos C, Gratziou C (2008) Exhaled breath markers in patients with obstructive sleep apnea. Sleep Breath 12:207–215PubMedCrossRef
Metadata
Title
Influence of CPAP treatment on airway and systemic inflammation in OSAS patients
Authors
Harun Karamanlı
Duygu Özol
K. Serife Ugur
Zeki Yıldırım
Ferah Armutçu
Bulent Bozkurt
Ramazan Yigitoglu
Publication date
01-05-2014
Publisher
Springer Berlin Heidelberg
Published in
Sleep and Breathing / Issue 2/2014
Print ISSN: 1520-9512
Electronic ISSN: 1522-1709
DOI
https://doi.org/10.1007/s11325-012-0761-8

Other articles of this Issue 2/2014

Sleep and Breathing 2/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.